Spring Creek Capital’s Orchestra BioMed OBIO Stock Holding History

Spring Creek Capital’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-46,394	Closed	-$460K	–	48
2022 Q1	$460K	Buy	+46,394	New	+$458K	0.02%	428

Other funds holding OBIO

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return

Spring Creek Capital's OBIO Position: Q2 2022 in Review

Spring Creek Capital sold out of Orchestra BioMed (OBIO) in Q2 2022, closing a stake of 46,394 shares — an estimated $460K sold.

Spring Creek Capital first reported a position in OBIO in Q1 2022 and held it in 1 quarter. The position peaked at $460K in Q1 2022. 62 funds tracked by Wall St. Rank hold OBIO as of Q2 2022.

Spring Creek Capital reported no remaining Orchestra BioMed position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 46,394 Orchestra BioMed shares in Q2 2022, an estimated $460K.
Spring Creek Capital first reported a position in Orchestra BioMed in Q1 2022 and held it in 1 quarter.
Spring Creek Capital's Orchestra BioMed position peaked at $460K in Q1 2022.
62 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.